2024
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care
Carbone M, Neuberger J, Rowe I, Polak W, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu G, Strazzabosco M, Cillo U. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care. Transplant International 2024, 36: 12190. PMID: 38332850, PMCID: PMC10850237, DOI: 10.3389/ti.2023.12190.Peer-Reviewed Original ResearchConceptsValue-based health careOutcome measuresEuropean Society of Organ TransplantationLiver transplantationDevelopment of outcome measuresConsensus statementOrgan transplantationValue-basedPatient-focusedAdvanced liver diseaseHealth careMultidisciplinary teamLiver diseaseTransplantationLife-savingEuropean Society for Organ TransplantationPatients
2023
SAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. SAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma. Journal Of Hepatology 2023, 78: s564-s565. DOI: 10.1016/s0168-8278(23)01358-2.Peer-Reviewed Original Research
2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatientsOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases
Kondo R, Kawaguchi N, McConnell MJ, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Sun Z, Utsumi T, Strazzabosco M, Iwakiri Y. Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases. Hepatology Research 2021, 51: 1000-1006. PMID: 34260803, PMCID: PMC8444906, DOI: 10.1111/hepr.13696.Peer-Reviewed Original ResearchCOVID-19 patientsVon Willebrand factorLiver injuryPatient's liverPapa Giovanni XXIII HospitalHigher serum ALTLiver sinusoidal endothelial cellsLiver biopsy samplesSinusoidal endothelial cellsSinusoidal thrombosisSerum ALTAST levelsPathological characteristicsHigher fibrinogenPlatelet microthrombiBiopsy samplesMultiple organsPatientsDisease severityCoronavirus diseaseLiverEndothelial cellsInjurySecondary damageWillebrand factorLiver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy
McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee A, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal Of Hepatology 2021, 75: 647-658. PMID: 33991637, PMCID: PMC8285256, DOI: 10.1016/j.jhep.2021.04.050.Peer-Reviewed Original ResearchConceptsLiver sinusoidal endothelial cellsLiver injuryInterleukin-6Sinusoidal endothelial cellsAlanine aminotransferaseLiver histologyD-dimerCOVID-19Primary human liver sinusoidal endothelial cellsSARS-CoV-2 infectionHuman liver sinusoidal endothelial cellsEndothelial cellsSoluble glycoprotein 130IL-6 levelsSmall-interfering RNA knockdownJAK inhibitor ruxolitinibFactor VIII activityProinflammatory factorsInflammatory signalsLarge cohortInhibitor ruxolitinibVWF antigenEndotheliopathyPatientsInjuryCholangiocarcinoma
Lasagni A, Strazzabosco M, Guido M, Fabris L, Cadamuro M. Cholangiocarcinoma. 2021, 231-259. DOI: 10.1007/978-3-030-65908-0_14.Peer-Reviewed Original ResearchTypes of cholangiocarcinomaDifferent epithelial cancersLiver transplantationGastrointestinal malignanciesMost patientsSurgical resectionRich tumor microenvironmentCurative treatmentChronic inflammationNegative marginsAggressive tumorsBiliary treeRare cancersRisk factorsCholangiocarcinomaAdvanced stageEpithelial cancersAnatomical locationTumor microenvironmentPatientsDistinct cancersCancerDesmoplastic natureMultimodal approachLaboratory tests
2019
Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology
Strazzabosco M, Cortesi P, Conti S, Okolicsanyi S, Rota M, Ciaccio A, Cozzolino P, Fornari C, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Zavaglia C, Perricone G, Munari L, Mantovani L, Belli L. Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology. Liver International 2019, 40: 60-73. PMID: 31654608, PMCID: PMC10916792, DOI: 10.1111/liv.14285.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCarcinoma, HepatocellularFemaleGastroenterologyHepatitis B, ChronicHepatitis C, ChronicHumansItalyLiver CirrhosisLiver NeoplasmsLongitudinal StudiesMaleMiddle AgedProspective StudiesQuality Indicators, Health CareSurvival AnalysisTreatment OutcomeValue-Based Health InsuranceConceptsClinical outcome indicatorsClinical practiceOutcome indicatorsChronic hepatitis BClinical practice settingMajor health problemCurrent international guidelinesNew effective treatmentsValue of careMETHODS/RESULTSHCV patientsHCV infectionHepatitis BClinical outcomesLiver diseaseMulticentre studyEffective treatmentHealth problemsInternational guidelinesCare deliveryValue-based medicineCostly treatmentPractice settingsHBVPatientsModeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma
Kokabi N, Nezami N, Xing M, Ludwig JM, Strazzabosco M, Kim HS. Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma. Journal Of Comparative Effectiveness Research 2019, 8: 993-1002. PMID: 31512955, DOI: 10.2217/cer-2019-0076.Peer-Reviewed Original ResearchConceptsTransplantation Network/United NetworkOrgan Sharing (UNOS) policyUnited NetworkNew Organ ProcurementHepatocellular carcinomaOrgan procurementOrthotopic liver transplantation outcomesLiver transplantation outcomesOrgan Sharing databaseOverall survivalPatient characteristicsSharing databaseTransplantation outcomesPatientsCarcinomaAMPTransplantationGroup
2018
Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals?
Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego A, Brunetto M, Raimondo G, Taliani G, Iannone A, Russo F, Santantonio T, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne E, Strazzabosco M, Massari M, Lampertico P, Rumi M, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta M, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A, Group P. Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? Liver International 2018, 38: 2190-2198. PMID: 29900654, PMCID: PMC6282782, DOI: 10.1111/liv.13901.Peer-Reviewed Original ResearchConceptsHCV elimination goalsElimination goalsBirth cohortHCV-endemic countriesLiver disease burdenCare scenariosHigh prevalence groupPublic health initiativesEligible patientsAntiviral treatmentPrevalence groupDisease burdenViraemic infectionsBurden estimatesEndemic countriesPatientsCare individualsHealth initiativesAbstractTextTreatment ratesCohortScreening strategyEligible poolTreatmentPotential strategyDynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions
Ippolito D, Querques G, Okolicsanyi S, Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. European Journal Of Radiology 2018, 106: 62-68. PMID: 30150052, DOI: 10.1016/j.ejrad.2018.07.012.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaAnti-angiogenic therapyPerfusion CT imagingHepatocellular carcinomaPerfusion parametersProgressor groupSurvival rateNon-progressor groupOverall survival rateKaplan-Meier analysisAssessment of responseAntiangiogenetic treatmentCirrhotic patientsSorafenib administrationPrognostic indicatorTumor responseTarget lesionsHCC lesionsIndividualized treatmentTumor neoangiogenesisPatientsOverall populationHigher survival rateCT imagingSurvival predictionLBP-021 The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European liver transplant registry
Perricone G, Mazzarelli C, Viganò R, Duvoux C, Cortesi P, Facchetti R, Vangeli M, Karam V, Adam R, Strazzabosco M, Belli L. LBP-021 The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European liver transplant registry. Journal Of Hepatology 2018, 68: s116. DOI: 10.1016/s0168-8278(18)30448-3.Peer-Reviewed Original Research
2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraftClinical presentation and outcomes of hepatocellular carcinoma in elderly patients referred to a tertiary center: 5-Years experience
Okolicsanyi S, Bonato G, Pontecorvi V, Ciaccio A, Gemma M, Strazzabosco M. Clinical presentation and outcomes of hepatocellular carcinoma in elderly patients referred to a tertiary center: 5-Years experience. Digestive And Liver Disease 2017, 49: e23. DOI: 10.1016/j.dld.2017.01.048.Peer-Reviewed Original ResearchSAT-106 Early changes in perfusion-computed tomography scan parameters as a marker of improved outcomes in patients with hepatocellular carcinoma treated with Sorafenib
Okolicsanyi S, Ippolito D, Querques G, Bonato G, Pontecorvi V, Corso R, Invernizzi P, Strazzabosco M. SAT-106 Early changes in perfusion-computed tomography scan parameters as a marker of improved outcomes in patients with hepatocellular carcinoma treated with Sorafenib. Journal Of Hepatology 2017, 66: s632. DOI: 10.1016/s0168-8278(17)31712-9.Peer-Reviewed Original Research
2016
Liver-allocation policies for patients affected by HCC in Europe
De Carlis L, Di Sandro S, Centonze L, Lauterio A, Buscemi V, De Carlis R, Ferla F, Sguinzi R, Okolicsanyi S, Belli L, Strazzabosco M. Liver-allocation policies for patients affected by HCC in Europe. Current Transplantation Reports 2016, 3: 313-318. PMID: 28473952, PMCID: PMC5410888, DOI: 10.1007/s40472-016-0117-6.Peer-Reviewed Original ResearchLiver allocation policyWaiting listCentro Nazionale TrapiantiOrgan SharingDeceased donor liver transplantLong-term survival ratesTransplant waiting listOrgan allocation systemOrgan allocation policyEtablissement français des GreffesLiver graftsLiver transplantLiver diseaseUnited NetworkNHS BloodSurvival rateDisease changesPatientsIs the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?
Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, Strazzabosco M, Belli LS. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? Journal Of Hepatology 2016, 66: 236-237. PMID: 27592303, DOI: 10.1016/j.jhep.2016.08.016.Peer-Reviewed Original Research
2015
Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients?
Cortesi P, Ciaccio A, Bellelli G, Rota M, Rota M, Cesana G, Mantovani L, Annoni G, Strazzabosco M. Should new antiviral treatments be considered in elderly Chronic Hepatitis C patients? European Journal Of Public Health 2015, 25: ckv175.222. DOI: 10.1093/eurpub/ckv175.222.Peer-Reviewed Original ResearchP0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis
Ciaccio A, Cortesi P, Bellelli G, Rota M, Rota M, Okolicsanyi S, Mantovani L, Annoni G, Strazzabosco M. P0811 : Sofosbuvir-based direct-acting antivirals treatment for elderly chronic hepatitis C patients: A cost-effectiveness analysis. Journal Of Hepatology 2015, 62: s639. DOI: 10.1016/s0168-8278(15)31014-x.Peer-Reviewed Original Research
2014
PGI29 The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation
Cortesi P, Mantovani L, Ciaccio A, Rota M, Cesana G, Strazzabosco M, Belli L. PGI29 The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation. Value In Health 2014, 17: a367-a368. PMID: 27200773, DOI: 10.1016/j.jval.2014.08.826.Chapters